{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:32Z","timestamp":1793640752659,"version":"4.5.1"},"reference-count":12,"publisher":null,"issue":"11","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    Development of a novel scale for assessing medical state in patients with new coronavirus infection based on clinical and laboratory disease severity's markers, named SHOKS-COVID scale.\n                    <jats:italic>Material and Methods<\/jats:italic>\n                    Clinical Assessment Scale (SHOKS-COVID) is based on1: clinical parameters (respiratory rate, Body temperature, SpO2 need and type of ventilation support) 2: Inflammation markers (C reactive protein (CRP) and prothrombotic marker (D-dimer)) and 3: percent of lungs injury by CT. This scale was used in several clinical studies in patients with varying severity of the course of the COVID 19. SHOKS-COVID scale was also compared against some additional biomarkers and with length of hospital stay.\n                    <jats:italic>Results<\/jats:italic>\n                    In patients with severe COVID-19 (Clinical Trial WAYFARER - 34 patients), SHOKS-COVID scores were correlated with the degree of inflammation: CRP (r = 0.64; p &lt;0.0001); the ratio lymphocytes \/ CRP (r = - 0.64; p &lt;0.0001). Also, SHOKS-COVID score correlated with the D-dimer (r = 0.35; p &lt;0.0001) and percentage lung damage on multispiral computed tomography (MSCT) - (r = 0.77, p &lt; 0.0001) and length stay in the clinic (r = 0.57, p = 0.0009). In patients with mild course (BISQUIT Study - 103 patients), SHOKS-COVID scores had a statistically significant positive correlation with length of fever (r = 0.37; p = 0.0002) and length of stay in the clinic (r = 0.52, p &lt;0.0001) and negatively correlated with the ratio of lymphocytes \/ CRP (-0.78, p &lt;0.0001) and the level of CRP (r=0.78; p &lt;0.0001). Patents were grouped based on severity of COVID 19 and median and interquartile range (IQR) of SHOCKS-COVID were measured in these groups. Median and IQR of SHOCKS-COVID were 2.00 [1.0-2.5] points in mild course, 4.0 points [3.0-5.0] in moderate course, 7.0 points [6.0-9.0] in moderately severe course,12.0 points [10.0-14.0] in severe course of disease and 15.0 points [14.5-15.5] in extremely severe patients.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    Here we report a novel scale of COVID 19 disease progression. This scale ranges from zero in asymptomatic patients (with normal range of biomarkers and without lung damage on CT) to fifteen in extremely severe patients. The scores for SHOKS-COVID are increasing, in parallel with the deterioration of all other biomarkers of severity and prognosis in patients with new coronavirus infection. Based on the analysis carried out, we were able to determine values of SHOKS-COVID scale and levels of main clinical and laboratory markers in patients with different severity of COVID 19.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2020.11.n1439","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T03:30:07Z","timestamp":1611545407000},"page":"35-41","source":"Crossref","is-referenced-by-count":17,"title":["How evaluate results of treatment in patients with COVID-19? Symptomatic Hospital and Outpatient Clinical Scale for COVID-19 (SHOCS-COVID)"],"prefix":"10.68900","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-2048","authenticated-orcid":true,"given":"V. Yu.","family":"Mareev","sequence":"first","affiliation":[{"name":"Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia\r\nFaculty of Fundamental Medicine, Lomonosov Moscow State University, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-6081","authenticated-orcid":true,"given":"Yu. L.","family":"Begrambekova","sequence":"additional","affiliation":[{"name":"Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia\r\nFaculty of Fundamental Medicine, Lomonosov Moscow State University, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1939-7189","authenticated-orcid":true,"given":"Yu. V.","family":"Mareev","sequence":"additional","affiliation":[{"name":"National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia\r\nRobertson Centre for Biostatistics, Glasgow, Great Britain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"ref1","unstructured":"World Health Organisation. COVID-19 Therapeutic Trial Synopsis. [Av. at: https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf]. 2020."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. 2020. [Av. at: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.17.20037432v4] DOI: 10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine. 2020; NEJMoa2015301. [Epub ahead of print]. DOI: 10.1056\/NEJMoa2015301","DOI":"10.1056\/NEJMoa2015301"},{"key":"ref4","unstructured":"Royal College of Physicians. National Early Warning Score (NEWS) 2. [Av. at: https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-earlywarning-score-news-2]. 2017."},{"key":"ref5","unstructured":"MediCalc. National Early Warning Score 2. [Internet] Available at: http:\/\/www.scymed.com\/en\/smnxpw\/pwfhc210.htm"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019\u20132020 epidemic: preparing intensive care units \u2013 the experience in Sichuan Province, China. Intensive Care Medicine. 2020;46(2):357\u201360. DOI: 10.1007\/s00134-020-05954-2","DOI":"10.1007\/s00134-020-05954-2"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Epidemiology. 2020. [Av. at: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.05.06.20092999.] DOI: 10.1101\/2020.05.06.20092999.","DOI":"10.1101\/2020.05.06.20092999"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054\u201362. DOI: 10.1016\/S0140-6736(20)30566-3","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z et al. D\u2010dimer levels on admission to predict in\u2010hospital mortality in patients with Covid\u201019. Journal of Thrombosis and Haemostasis. 2020;18(6):1324\u20139. DOI: 10.1111\/jth.14859","DOI":"10.1111\/jth.14859"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Krasnova T.N., Malahov P.S. et al. Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiia. 2020;60(6):15\u201329. DOI: 10.18087\/cardio.2020.6.n1226","DOI":"10.18087\/cardio.2020.6.n1226"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A., Plisyk A.G. et al. Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial \u201cBromhexIne and Spironolactone for Coron\u0430virUs Infection requiring hospiTalization (BISCUIT)\u201d. Kardiologiia. 2020;60(8):4\u201315. DOI: 10.18087\/cardio.2020.8.n1307","DOI":"10.18087\/cardio.2020.8.n1307"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A. et al. Results of an open prospective controlled comparative study on the treatment of new coronavirus infection (COVID-19): Bromhexine and spironolactone for the treatment of coronavirus Infection requiring hospitalization (BISCUIT). Kardiologiia. 2020;60(11). DOI: 10.18087\/cardio.2020.11.1440","DOI":"10.18087\/cardio.2020.8.n1307"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1439\/933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:45Z","timestamp":1793639865000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.11.n1439","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}